Trials / Recruiting
RecruitingNCT06773403
Upadacitinib for Prurigo Nodularis
A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Upadacitinib | All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary. |
Timeline
- Start date
- 2024-04-09
- Primary completion
- 2025-12-01
- Completion
- 2026-01-01
- First posted
- 2025-01-14
- Last updated
- 2025-01-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06773403. Inclusion in this directory is not an endorsement.